Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance

International Journal of Cardiology
Sabine PerlThomas C Wascher

Abstract

Hypertensive patients with IGT have increased risk for cardiovascular disease and progression to diabetes mellitus. Clinical trials suggest that the ARB telmisartan uniquely possesses PPARγ agonistic properties and improves insulin resistance as well as vascular endothelial dysfunction. The aim of the present study was to compare vascular effects of telmisartan and losartan in relation to their metabolic and antihypertensive effects in hypertensive patients with IGT. 24 patients were randomised in a double-blind, prospective, cross-over trial. At baseline and after 12 weeks of either treatment an oGTT, and endothelial function testing was performed. Endothelial function improved significantly by telmisartan treatment but not by losartan treatment (FMD; T: 7.9 ± 0.7%, vs B: 6.4 ± 0.8, p<0.01; vs L: 6.4 ± 0.6, p<0.001) at almost identical antihypertensive effect of both agents. Insulin resistance assessed by HOMA (T: 2.20 ± 0.47 vs B: 3.04 ± 0.60, p<0.01; vs L: 3.38 ± 0.84, T vs L p<0.05) and ISI120 (T: 0.114 ± 0.003 vs B: 0.092 ± 0.002, p<0.001; vs L: 0.090 ± 0.006, T vs L p<0.01) improved significantly after telmisartan only, as did glucose tolerance (p<0.01). The improvement of the endothelial function observed, significantly ...Continue Reading

References

Oct 29, 1996·Proceedings of the National Academy of Sciences of the United States of America·L A VellosoC R Kahn
Apr 4, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·J P NewM Walker
May 3, 2001·The New England Journal of Medicine·J TuomilehtoUNKNOWN Finnish Diabetes Prevention Study Group
Jun 28, 2002·Lancet·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trail Research Group
Jun 28, 2002·Diabetes·Christine C JensenUNKNOWN American Diabetes Association GENNID Study Group
Jul 27, 2002·Journal of the American College of Cardiology·Maria G ModenaRosario Rossi
Apr 30, 2003·Hypertension·Lorenzo GhiadoniAntonio Salvetti
Jun 17, 2004·Circulation·Jean Davignon, Peter Ganz
Apr 13, 2005·Lancet·Michael StumvollTimon W van Haeften
Jul 28, 2005·Diabetes·Bart Staels, Jean-Charles Fruchart
Dec 7, 2005·Journal of Hypertension·Giuseppe ManciaAlberto Zanchetti
Aug 22, 2006·Metabolism: Clinical and Experimental·Jutta M NagelKlaus G Parhofer
Aug 22, 2006·Metabolism: Clinical and Experimental·Ralf A BenndorfRainer H Böger
Sep 19, 2006·The New England Journal of Medicine·UNKNOWN DREAM Trial InvestigatorsRury R Holman
Dec 2, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Satoshi MorimotoKatsunori Sawada
Jan 31, 2007·Diabetes Care·Joshua A BeckmanMark A Creager
Dec 1, 2007·Journal of Cardiovascular Pharmacology·Ralf A BenndorfRainer H Böger
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Dec 3, 2008·International Journal of Cardiology·Andrew J S Coats

❮ Previous
Next ❯

Citations

Apr 23, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Eberhard SchulzThomas Münzel
Jun 3, 2014·Cardiovascular Diabetology·Norbert J TripoltHarald Sourij
Jan 10, 2014·Journal of Atherosclerosis and Thrombosis·Mizuho KinouchiToshio Matsumoto
Apr 11, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hisato Takagi, Takuya Umemoto
Aug 26, 2014·Journal of the American Society of Hypertension : JASH·Hisato TakagiUNKNOWN All-Literature Investigation of Cardiovascular Evidence Group
Sep 12, 2015·HIV Clinical Trials·Jordan E LakeJudith S Currier
Dec 24, 2011·International Journal of Cardiology·Hisato Takagi, Takuya Umemoto
Dec 12, 2012·International Journal of Cardiology·Hisato TakagiUNKNOWN for ALICE (All-Literature Investigation of Cardiovascular Evidence) Group
Mar 20, 2013·BioMed Research International·Miroslav RadenkovićMilica Prostran
Jul 22, 2016·Journal of Pharmacology & Pharmacotherapeutics·Sandesh Madhukar Bharati, Nishith Singh
Dec 10, 2016·The Indian Journal of Medical Research·Miroslav RadenkovicMilica Prostran
Nov 3, 2017·Journal of Atherosclerosis and Thrombosis·Ryo ShimomuraMasayasu Matsumoto
Feb 5, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Annabella Braschi
Jun 18, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Takehiko WagoYukio Hirata
May 24, 2016·Archiv der Pharmazie·Olayinka O AjaniIfedolapo O Olanrewaju

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.